Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Harrold, Leslie; Reed, George; Kremer, Joel; Curtis, Jeffrey; Solomon, Daniel; Hochberg, Marc; Kavanaugh, Arthur; Saunders, Katherine; Shan, Ying; Spruill, Tanya; Pappas, Dimitrios; Greenberg, Jeffrey
• Is Part Of: Arthritis research & therapy. Volume 18:Issue 1(2016)
• Page Start: 1
• Page End: 8
• Publication Date: 2016-12
• Subjects: Disease-modifying antirheumatic drugs -- Rheumatoid arthritis -- American College of Rheumatology; Arthritis -- Periodicals; Arthritis -- Treatment -- Periodicals; 616.722005
• DOI: 10.1186/s13075-016-0992-3
• Languages: English
• ISSNs: 1478-6362

Abstract

Abstract Background Factors associated with care concordant with the American College of Rheumatology (ACR) recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) are unknown. Methods We identified a national cohort of biologic-naive patients with RA with visits between December 2008 and February 2013. Treatment acceleration (initiation or dose escalation of biologic and nonbiologic DMARDs) in response to moderate to high disease activity (using the Clinical Disease Activity Index) was assessed. The population was divided into two subcohorts: (1) methotrexate (MTX)-only users and (2) multiple nonbiologic DMARD users. In both subcohorts, we compared the characteristics of patients who received care consistent with the ACR recommendations (e.g., prescriptions for treatment acceleration) and their providers with the characteristics of those who did not at the conclusion of one visit and over two visits, using logistic regression and adjusting for clustering of patients by rheumatologist. Results Our study included 741 MTX monotherapy and 995 multiple nonbiologic DMARD users cared for by 139 providers. Only 36.2 % of MTX monotherapy users and 39.6 % of multiple nonbiologic DMARD users received care consistent with the recommendations after one visit, which increased over two visits to 78.3 % and 76.2 %, respectively (25–30 % achieved low disease activity by the second visit without DMARD acceleration). Increasing time since the ACR publication on RA treatment recommendations was not associated with improved adherence. Conclusions Allowing two encounters for treatment acceleration was associated with an increase in care concordant with the recommendations; however, time since publication was not.